China's first batch of generic Semaglutide drugs is on the way, and weight loss medications will enter the "bargain price" era.

With the weight-loss drug giant Novo Nordisk’s blockbuster GLP-1 class drug semaglutide’s core molecule patent in China set to expire in March, a large number of domestically made semaglutide generics from Chinese local manufacturers are on track to be approved. According to publicly available information, on China’s domestic market, including companies such as Jiuyuan Gene, Livzon Group, China Resources Pharmaceutical (East China Pharmaceutical), Qilu Pharmaceuticals, and Simcere Pharmaceutical, more than a dozen local pharmaceutical companies’ semaglutide generic drugs are expected to be launched in the near future, and more than ten additional products are in Phase 3 clinical trials—an impending price war is about to sweep through the market. A senior endocrinology expert told a reporter that as more generics are launched, weight-loss drugs will soon enter a “rock-bottom price” era. (First Financial)